Related by context. All words. (Click for frequent words.) 84 AACR Symposium 77 AACR symposium 72 AACR NCI EORTC 72 Late Breaker 71 Preclinical Data 71 EORTC NCI AACR 71 AACR #st Annual Meeting 70 Molecular Targets 70 #th Annual Interscience 69 AACR San Antonio 69 Combination REOLYSIN R 69 EORTC NCI AACR Symposium 68 Clinical Trial Results 68 #rd Annual CTRC 68 Randomized Phase 68 Phase 2b Clinical Trial 67 Genitourinary Cancers Symposium 67 Gastrointestinal Cancers Symposium 67 Preclinical Study 67 SABCS 67 virus HCV protease inhibitor 67 Oral Fingolimod 67 Presents Positive 67 Selective Cardiac Myosin 67 Initiate Phase 67 ORAL Sync 67 NASDAQ CYTK announced 67 Completes Patient Enrollment 67 AACR IASLC Joint 67 Presents Preclinical Data 67 Poster Presentations 66 #th Interscience Conference 66 Clinical Trials Update 66 RECORD1 66 Pivotal Phase III 66 Brentuximab Vedotin SGN 66 ongoing Phase 1b 66 Society CTOS 66 ASCO Annual Meeting 66 NASDAQ CXSP announced 66 NASDAQ ARRY 66 GLOBE NEWSWIRE Cyclacel Pharmaceuticals 66 evaluating tivozanib 66 Presents Preclinical 66 MT# MEDI 66 HCV NS5B polymerase 66 adecatumumab MT# 65 Inc. Nasdaq IMGN 65 nd Annual Meeting 65 Metastatic Melanoma 65 AASLD Meeting 65 Randomized Phase II 65 Sangamo BioSciences Announces 65 CD# CEA 65 Symposium SABCS 65 II Clinical Trial 65 Therapeutics TCT scientific 65 ICAAC IDSA 65 CTRC AACR San Antonio 65 sarcoma melanoma 65 Study Evaluating 65 FOLOTYN ® 65 Solorel TM 65 fosbretabulin 64 telomerase inhibitor drug 64 AAG geldanamycin analog 64 MEK Inhibitor 64 ASCO GI 64 Preclinical Efficacy 64 Telik logo TELINTRA 64 Hsp# Inhibitor 64 non nucleoside inhibitor 64 pralatrexate injection folate analogue 64 Vaccine Adjuvant 64 BiTE R 64 Vascular Disrupting Agent 64 Announces Poster Presentations 64 Canaccord Adams Hepatitis C 64 Randomized Double blind 64 ThermoDox ® clinical 64 Phase III Clinical Trial 64 HDAC Inhibitor 64 transthyretin TTR mediated amyloidosis 64 ASH Annual Meeting 64 Pivotal Phase 64 Kinase Inhibitor 64 BiTE antibodies targeting 64 SUCCEED trial 64 Phase IIb Clinical Trial 64 R roscovitine CDK cyclin 64 Phase Ib Clinical Trial 64 Phase III ALLEGRO 64 Double Blind Placebo 64 ABCSG 64 PROSTASCINT R 64 Inc. NASDAQ HEPH 64 First Patient Enrolled 64 RNAi Therapeutic 64 Reports Preclinical Data 64 ICAAC 63 Poster Presentation 63 #st Annual Meeting 63 BRIM3 63 Chicago Multidisciplinary Symposium 63 Safety Tolerability 63 Abstract Number 63 Rheumatology ACR Annual 63 JAK2 Inhibitor 63 Prostate Cancer Symposium 63 Collaborators Present 63 MCSP respectively 63 Initiates Phase II 63 Prostate AdenoCarcinoma Treatment 63 CYT# potent vascular disrupting 63 abstracts summarizing 63 Inflammatory Arthritis 63 Breast Cancer Symposium 63 FOLFOX6 chemotherapy regimen 63 Nasdaq AEGR 63 REG2 63 Arteriosclerosis Thrombosis 63 Biological Therapy 63 Hematological Malignancies 63 AACR #nd Annual Meeting 63 Meets Primary Endpoint 63 Connective Tissue Oncology 63 HCV Protease Inhibitor 63 European CanCer Organisation ECCO 63 By JENNIFER LEARN 63 AACR Meeting 63 dependent kinase inhibitor 63 CROI 63 Melanoma Skin Cancers 63 Initiates Enrollment 62 UEGW 62 Initiates Phase III 62 IL# PE#QQR 62 R roscovitine 62 Clinical Oncology Annual Meeting 62 Completes Enrollment 62 Phase 2b Trial 62 Initiated Phase 62 Synta Announces 62 Telik Announces 62 candidate CRLX# 62 REVIVE TA 62 R lenalidomide 62 Sapacitabine 62 BIOCOM Investor Conference 62 Initiates Phase 62 Antiviral Activity 62 Oral Calcitonin 62 Prolongs Survival 62 INSPIRE Trial Phase III 62 GVAX ® 62 evaluating satraplatin 62 mitogen activated ERK kinase 62 histone deacetylase HDAC inhibitor 62 lintuzumab SGN 62 ASCO Gastrointestinal Cancers Symposium 62 Phase #b/#a clinical 62 Poster Discussion 62 multicenter Phase III 62 Oral Presentation 62 Anti Tumor 62 Begins Dosing 62 MT#/MEDI-# 62 Advanced Neuroendocrine Tumors 62 Inc. Nasdaq ATHX 62 Topline Results 62 Successfully Completes Phase 62 Phase Ib clinical trials 62 novel orally inhaled 62 Rigel R# 62 ASCO GU 62 Hormone Refractory Prostate Cancer 62 Drug Candidate 62 TO AVOID PREGNANCY WHILE 62 Pooled Analysis 62 phase IIb clinical 62 IMPACT DCM 62 Receives Orphan Drug Designation 62 Opportunistic Infections CROI 62 PSN# [002] 62 preclinical efficacy 62 Phase Ib II 62 PRNewswire FirstCall Genaera 62 Phase 2a Clinical Trial 62 Demonstrates Significant 62 Initiates Clinical Trial 62 ALN TTR 61 multicenter Phase II 61 Chemotherapy ICAAC 61 systemic anaplastic large 61 Phase IIb Trial 61 number NCT# ClinicalTrials.gov 61 mGluR5 negative 61 Nasdaq ENZN 61 phase IIb study 61 Phase #/#a trial 61 Prospective Randomized 61 Crofelemer budesonide foam 61 VEGFR2 inhibitor 61 Inc. Nasdaq AVRX 61 lexidronam injection 61 Zenvia ™ 61 PNP inhibitor 61 LENALIDOMIDE 61 anionic backbone 61 Digestive Disease Week DDW 61 EORTC NCI 61 Dose Escalation 61 Submits Response 61 entitled Synergistic 61 Trial Evaluating 61 Polymerase Inhibitor 61 refractory chronic lymphocytic 61 HGS ETR2 61 targeting CD# 61 Treatment Naïve 61 NASDAQ INHX 61 PEG SN# 61 TransVax TM 61 BIO InvestorForum 61 ECTRIMS 61 Nasdaq GNTA 61 www.telik.com 61 cetuximab Erbitux R 61 Hedgehog Pathway Inhibitor 61 TKB# 61 Proc Am Soc 61 ECCMID 61 PRN FDA Approves 61 GVAX R 61 multicenter Phase 61 Cancer Cachexia 61 Mg Usa 61 compound AEZS 61 Annual ICAAC 61 including eniluracil ADH 61 sunitinib Sutent ® 61 oral prodrug 61 Phase 2a Trial 61 Inc. Nasdaq BIOD 61 Hematology Annual Meeting 61 initiated Phase Ib 61 First Patient Dosed 61 dose escalation clinical 61 novel VDA molecule 61 Novel Oral 61 Deforolimus 61 Pharmacokinetics PK 61 PERSEUS 61 Relapsing Multiple Sclerosis 61 Webcast Discussion 61 Nasdaq SGMO announced 61 essential thrombocythemia ET 61 Phase 2a Study 61 Breaking Clinical Trials 61 #nd Annual Meeting 61 Oral Presentations 61 Xcytrin R 61 SinuNase ™ 60 huC# DM4 60 crizotinib PF # 60 Safinamide 60 REVIVE Diabetes 60 Phase 1b clinical trials 60 Nasdaq IDRA today 60 Pediatric Academic Societies PAS 60 Immunotherapeutic 60 NASDAQ IDRA 60 Inc. Nasdaq VRUS 60 Vaccine Protects Against 60 Perifosine KRX 60 Solazed TM 60 includes TOLAMBA TM 60 Previously Treated 60 Phase 2a clinical 60 estrogen receptor beta agonist 60 AACR EORTC NCI 60 Phase 1a clinical 60 Abstract Accepted 60 ExTRACT TIMI 60 orally inhaled migraine 60 systemic Phase 1b 60 novel histone deacetylase 60 ALN HPN 60 dasatinib Sprycel ® 60 FASEB J. 60 Cancer Immunotherapy 60 Poster Session 60 agonistic human 60 Ovarian PLCO Cancer 60 Refractory Hodgkin Lymphoma 60 Inc. Nasdaq ALSE 60 Endocrine Society Annual Meeting 60 ATRA IV 60 Tanespimycin 60 ACR ARHP 60 Pre RELAX AHF 60 Annual Transcatheter Cardiovascular 60 HCV SPRINT 60 AN# topical anti 60 XL# anticancer compounds 60 Nasdaq NYMX 60 Phase 1b Clinical Trial 60 randomized discontinuation trial 60 Carfilzomib 60 sorafenib tablets 60 BCIRG 60 trastuzumab Herceptin R 60 Initiates Clinical 60 Glufosfamide 60 Breast Cancer Symposium SABCS 60 pan HDAC inhibitor 60 annual Transcatheter Cardiovascular 60 TRANSFORMS 60 Tezampanel 60 ON #.Na 60 Guanilib 60 AASLD 60 Patient Enrollment 60 Related Disorders ICAD 60 Cancer Therapeutic 60 Malignant Lymphoma 60 Phase III AFFIRM 60 bazedoxifene conjugated estrogens 60 vapreotide acetate 60 Inc. www.micromet inc.com 60 preclinical pharmacokinetic 60 randomized controlled Phase 60 intravesical infusion therapy 60 Aflibercept 60 TM Aganocide 60 Antitumor Activity 60 programs visit http:/www.bionovo.com 60 Licenses Novel 60 TASKi2 60 Personalized Immunotherapy 60 CTRC AACR 60 Trofex TM 60 Solid Tumors 60 novel defensin mimetic 60 Zenvia Phase III 60 International Myeloma Workshop 60 CompilerParameters options CodeCompileUnit 60 satraplatin Phase 60 ERA EDTA 60 investigational humanized monoclonal antibody 60 Romiplostim 60 BRIM2 60 Vicriviroc 60 DETECTS POSSIBLE BULLISH HARAMI 60 CYP#A# CYP#D# 60 OTCBB AOLS announced 60 BiTE antibody MT# 60 Novel Inhibitor 59 assessing T DM1 59 Tyrosine Kinase Inhibitor 59 pharmacogenomic translational research 59 Phase III placebo controlled 59 Nasdaq SNSS 59 CALGB # [002] 59 AVADO 59 bapineuzumab AAB 59 Annual Scientific Sessions 59 humanised monoclonal antibody 59 pan histone deacetylase 59 ASCO Genitourinary Cancers Symposium 59 evaluating picoplatin 59 ASCO Breast Cancer 59 E CENP E 59 Submits NDA 59 alpha antagonist 59 NASDAQ TARG 59 Active Biotech NASDAQ OMX 59 EASL 59 Targanta Therapeutics Corporation 59 J Antimicrob Chemother 59 interferon gamma 1b 59 oral proteasome inhibitor 59 Recurrent Chest Wall 59 NASDAQ LGND 59 Xeloda ® 59 peptidic compound 59 orally administered inhibitor 59 registrational Phase 59 antibody blinatumomab MT#/MEDI-# 59 Nasdaq IMGN 59 oral picoplatin 59 TG MV 59 HDAC Inhibitors 59 PEGylated interferon beta 1a 59 PROVENGE sipuleucel T 59 ISPOR 59 evaluating mipomersen 59 Phase Ib clinical 59 midstage clinical 59 RCW Breast Cancer 59 Inc. Nasdaq RDYN 59 antibody MT# 59 please visit http:/www.atherogenics.com 59 Randomized Phase III 59 PSMA ADC 59 selective androgen receptor modulator 59 dextromethorphan quinidine 59 Severe Sepsis 59 Cites Positive 59 PANVAC VF 59 GLOBE NEWSWIRE Pressure BioSciences 59 Demonstrates Sustained 59 CDK cyclin dependent 59 Vaxfectin R adjuvant 59 Dendritic Cells 59 Phase 2a trial 59 Active Ulcerative Colitis 59 telomerase therapeutic 59 humanized therapeutic 59 phase Ib 59 Therapeutics TCT 59 compound INCB# 59 AHA Scientific Sessions 59 familial amyloidotic polyneuropathy FAP 59 Targeted Therapies 59 Initiates Phase 2b 59 EULAR Annual 59 Selective Cardiac Myosin Activator 59 Refractory Angina 59 plus Copegus R 59 liposomal formulation 59 phase IIa clinical 59 Intervention Effectiveness 59 Phase Ib study 59 RNAi Therapeutics 59 DETECTS POSSIBLE BEARISH INSIDE 59 Inc. Nasdaq AMLN 59 Phase 2b Study 59 Nasdaq CYCC Nasdaq CYCCP 59 selective kinase inhibitor 59 CTI Nasdaq 59 ENDEAVOR III 59 Completes Dosing 59 Alzheimer Disease ICAD 59 Nasdaq OPTR 59 Phase III ADT 59 FORECASTS PROJECTIONS EXPECTATIONS OR 59 metastatic castration resistant 59 NuroPro ® AD 59 AUA Annual Meeting 59 CIMZIA TM certolizumab pegol 59 RANK Ligand inhibitor 59 Clinical Oncology ASCO Annual 59 J.P. Morgan Healthcare 59 platform HDL Mimetic 59 Small Molecule 59 generation Hsp# inhibitor 59 Pivotal Trial 59 Nephrol Dial Transplant 59 Pharmacodynamic 59 modified glutathione analog 59 IMPACT IMmunotherapy 59 BR.# 59 PRNewswire FirstCall Genta Incorporated 59 GVAX Immunotherapy 59 ThermoDox R 59 OR THE APPLICABLE 59 Romidepsin 59 Genitourinary Cancer 59 Budesonide foam crofelemer 59 HDL Selective Delipidation 59 Inc. NASDAQ SGEN 59 CALGB 59 Molecular Cancer 59 Panzem R 59 ALN VSP Phase 59 chemotherapy FOLFOX 58 Announcement acc 58 WHO TOOK 58 serine protease inhibitor 58 AIR2 Trial 58 Advanced Renal Cell 58 Semafore Pharmaceuticals 58 MEND CABG 58 demonstrated antitumor activity 58 www.micromet inc.com 58 5 Fluorouracil 58 ARVO 58 alvespimycin 58 ENMD # 58 fidaxomicin Phase 58 HDL Mimetic Peptide 58 EXPAREL ™ 58 investigational monoclonal antibody 58 XOMA 3AB 58 Unstable Angina 58 Keystone Symposia 58 Exelixis compounds 58 Trastuzumab DM1 58 ECCO ESMO 58 Recombinant Human 58 brivanib 58 itraconazole Sporanox 58 Transcatheter Cardiovascular Therapeutics TCT 58 Clinical Trial Data 58 Antibody Drug Conjugate 58 ALLSCHWIL BASEL SWITZERLAND 58 Receives Milestone Payment 58 CRLX# 58 Panzem NCD 58 oral nucleoside analogue 58 transthyretin TTR 58 proteasome inhibitor 58 potent suppressor 58 clinical trials dacetuzumab SGN 58 BOTHELL Wash. Business Wire 58 phase IIb trial 58 DG# compounds targeting 58 Elagolix 58 Molecular Origins 58 Pivotal Clinical Trial 58 NicVAX TM 58 trial evaluating PRX# 58 st Annual Meeting 58 EXPAREL TM 58 Shows Promising 58 Aggressive Reduction 58 brand ciclesonide HFA 58 PRNewswire FirstCall Nektar Therapeutics 58 Initiate Phase III 58 Chronic Lymphocytic Leukemia CLL 58 trastuzumab DM1 T DM1 58 HGS ETR1 mapatumumab 58 Ozarelix 58 Healthcare Conferences 58 LymphoStat B TM 58 Potent Antiviral Activity 58 Phase III Pivotal 58 Achieves Primary Endpoint 58 pharmacokinetic PK 58 XL# XL# XL# 58 novel synthetic PEGylated 58 Projected Release Date 58 Ovitrelle R Serostim 58 Modulates 58 Endocrine Society #nd 58 coronary stent merged 58 Antimicrobial Agents 58 MKC# MT 58 SAR# [004] 58 Clinical Antipsychotic Trials 58 PHRM 58 Phase 1b trial 58 RGB # 58 XL# SAR# 58 Inc. Nasdaq OPTR 58 vitro pharmacology 58 MidnightTrader.com March 58 worsening thrombocytopenia 58 CLARITY study 58 DEERFIELD Ill. Business Wire 58 ITS QUARTERLY RESULTS 58 Pharmacokinetic 58 Am J Epidemiol 58 phase IIIb 58 League Against Rheumatism 58 PI3K/mTOR 58 2 methoxyestradiol 58 Prednisone Against Refractory 58 relapsed MM 58 rALLy clinical trial 58 SPL# Gel vaginal microbicide 58 BREAKS ABOVE 3 58 J Clin Oncol 58 hyaluronidase enzyme 58 TLK# 58 NOT RAISED BELOW 58 TELINTRA R 58 R# #mg BID 58 Medical Oncology ESMO 58 abnormal p# 58 HCV polymerase inhibitors 58 Investigational Oral 58 PHASE III 58 radiation sensitizer 58 recombinant PSMA vaccine 58 Folfox 58 NU# direct 58 NYSE Amex RGN 58 BiTE ® 58 Systemic Sclerosis 58 radezolid 58 Announces Presentation 58 PRT# 58 J Allergy Clin 58 Eluting Stent 58 Granted Orphan Drug 58 AACR Annual Meeting 58 highly selective inhibitor 58 Pluristem Therapeutics 58 MAGE A3 ASCI 58 TRX1 58 Cannabinor 58 novel emulsion formulation 58 Rheumatology Annual 58 Kahalalide F 58 Frankfurt XMP 58 registrational trial 58 PF # [002] 58 erlotinib Tarceva ® 58 Seliciclib 58 Genta Incorporated OTCBB 58 docetaxel Taxotere R 58 PRNewswire FirstCall Tercica 58 Inc. Nasdaq SGEN 58 PEGylated anti 58 BIOV 58 EOquin TM phase 58 HuMax EGFr 58 Cutaneous T 58 elotuzumab 58 Antiviral Research 58 Complicated Skin 58 Endocrine Society #st 58 Digestive Disease Week 57 Multiple Ascending Dose 57 alpha folate receptor 57 J Am Coll 57 KRN# 57 CAMMS# 57 Antigen Specific 57 Mouse Model 57 RELEASE ACCORDING TO 57 Renal Cell Carcinoma 57 triggers apoptosis programmed 57 Factor Receptor 57 developing ACAPODENE 57 Cambridge Healthtech Institute 57 Cloretazine ® 57 vivo efficacy 57 Corporation Nasdaq PHRM 57 AVN# Phase 57 ZYBRESTAT fosbretabulin 57 kidney urologic 57 PCI ExTRACT TIMI 57 Cancers Symposium 57 Nasdaq PCYC 57 novel antimitotic agent 57 Gynecologic Cancer Society 57 MEK inhibitor 57 Omacetaxine 57 alfa 2a 57 Acute Ischemic Stroke 57 DNA demethylating agent 57 Developmental Therapeutics Immunotherapy 57 pentadentate logo R 57 BioCentury Future Leaders 57 www.labopharm.com 57 Infectious Diseases ECCMID 57 SPIRIT FIRST 57 NO# [002] 57 markets Testim ® 57 Arch Neurol 57 PEGylated Fab fragment 57 AIXTRON AG FSE AIX 57 ANN INTERN MED 57 small molecule activator 57 PRNewswire FirstCall Bionovo 57 non nucleoside HCV 57 COMPANY ASSUME ANY RESPONSIBILITY 57 J Am Soc 57 AACR Frontiers 57 CCR5 mAb 57 Platelet Inhibition 57 systemically administered 57 seliciclib CYC# 57 oral ridaforolimus 57 PEG irinotecan 57 AND INCREASING 57 Genta Incorporated OTCBB GETA 57 Sym# 57 ID NCT# 57 RhuDex TM 57 R sorafenib tablets 57 FROM NOON 57 CB2 selective receptor agonist 57 Adenoviral 57 Nasdaq INCY announced 57 Upcoming Conferences 57 nonclinical studies 57 Suppl. 57 panitumumab Vectibix R 57 humanized interleukin 6 57 Clin Chem 57 NEUVENGE 57 Bazedoxifene 57 Abstract # 57 EGS# 57 Receives Orphan Drug 57 TO DETECT 57 Gastrointestinal Stromal Tumors 57 Systemic Delivery 57 clinical trials SGN 57 Amigal TM 57 Randomised Trial 57 FALLS BELOW 3 57 EVEREST II 57 monoclonal antibody IgG1 Mab 57 Ambrisentan 57 ganetespib 57 NASDAQ SLXP today 57 Cardiotoxicity 57 PERSEUS clinical program 57 AVERROES 57 papillary renal cell carcinoma 57 Vidaza ® 57 ENESTnd 57 tramiprosate Alzhemed TM 57 ALN PCS 57 Vaccine Immunology 57 DNA methyltransferase inhibitors 57 PRNewswire FirstCall Amylin Pharmaceuticals 57 Potassium Chloride Sodium Ascorbate 57 Blinatumomab 57 CRMD# 57 Amrubicin 57 Aplidin R 57 PEG IFN 57 class anticancer quinolone 57 davunetide intranasal AL 57 KSP inhibitor 57 cisplatin gemcitabine 57 tumor xenograft models 57 Regeneron Pharma 57 oral dihydropyrimidine dehydrogenase DPD 57 clinical trials Archexin ® 57 Upcoming Presentation 57 FEMALES SHOULD BE ADVISED 57 phenyl salicylate methylene blue 57 PKC# 57 Vascular Biology ATVB 57 Endocrine Society ENDO 57 HGS ETR1 57 liposome injection 57 allosteric modulator NAM 57 Meta Analysis 57 Nasdaq CYTX 57 QLT# 57 Retroviruses 57 Beneficial Effects 57 Vitrasert R 57 Castration Resistant Prostate Cancer 57 targeted radiotherapeutic 57 Gastrointestinal Cancer 57 CCNMATTHEWS 57 delafloxacin 57 technology Parthenogenesis 57 antiangiogenic activity 57 Ann Rheum Dis 57 phase IIa 57 motexafin gadolinium Injection 57 vascular disrupting agent 57 MSCRAMM ® 57 Multicenter 57 Hematology ASH Annual Meeting 57 hemagglutination inhibition HAI 57 PRNewswire FirstCall Kensey Nash 57 mapatumumab 57 RAS MAPK pathway 57 pharmacokinetic PK study 57 RhuDex R 57 SinuNase TM 57 Ophena TM 57 candidate AQ4N 57 Adjuvant Treatment 57 recurrent glioblastoma multiforme 57 Kidney Int 57 candidates Azedra TM 57 histone deacetylase inhibitor 57 bevirimat Study 57 CCX# 57 CYC# 57 ADA Scientific Sessions 57 Antisoma AS# 57 XL# inhibits 57 multicenter phase 57 Shows Promise Against 57 Phase #/#a 57 axitinib 57 MERIT ES 57 LUMINATE 57 PEGylated irinotecan 57 PRNewswire FirstCall Pharmacopeia 57 teriflunomide 57 Trofex 57 AEGR 57 resistant hormone refractory 57 PROTECT AF 57 Investigational Compound 57 Albuferon TM 57 doi #.#/fj.#-# 57 NEWS RELEASE THE COMPANY 57 OFFICE SAYS 57 CEQ# 57 THE GERMAN SECURITIES 57 Endovascular Valve Edge 57 journal Antimicrobial Agents 57 Edge STudy 57 depsipeptide 57 Gastrointestinal Oncology 57 XPEL Announces 57 metaglidasen 57 epoetin beta 56 Multicenter Study 56 INCB# [001] 56 Phase IIA 56 Bezielle 56 VOLUME WATCH FOR 56 ARIKACE ™ 56 BOLDER II 56 randomized Phase III 56 ospemifene 56 forodesine 56 Arch Intern Med 56 IS DETAILED IN 56 LAST QUARTER ANNUALIZED SALES 56 Ostarine ™ 56 cows boners #-# 56 benzoic acid hyoscyamine sulfate 56 dose escalation Phase 56 Investigational Drug 56 sapacitabine CYC# 56 topical antifungal product 56 Ophthalmic Drugs Advisory 56 Onyx Pharmaceuticals Announces 56 bevacizumab Avastin R 56 PreCISe 56 Cimzia ® certolizumab pegol 56 SPRYCEL ® 56 OMP #R# 56 nilotinib Tasigna ® 56 imatinib Gleevec ® 56 comparing alemtuzumab 56 developing ostarine selective 56 Ann Oncol 56 liposomal doxorubicin 56 R#/MEM # 56 Podium Presentation 56 Aurora Kinase 56 maximally tolerated dose 56 LungAlert TM 56 AND SHOULD ALSO 56 Belimumab 56 receiving INTRON 56 induced mucositis 56 ocular formulation 56 CEO www.squeezetrigger.com +#-#-#-# 56 LUX Lung 56 BY RYAN ERNST 56 Ocrelizumab 56 IMC #B 56 J Natl Cancer Inst 56 Inc. OTCBB LPTN 56 Antiangiogenic 56 Nordic ACTI 56 J Clin Endocrinol Metab 56 Am J Pathol 56 PD LID 56 Subtypes 56 Phase IIB 56 OTCBB AOLS 56 selective inverse agonist 56 chemosensitizer 56 INTERNET PHONE NO 56 small molecule tyrosine 56 undergoing elective percutaneous 56 Relapsed Refractory Multiple Myeloma 56 FOLFOX6 56 LibiGel ® 56 GENR 56 LBH# 56 EFNS 56 APOPTONE 56 perifosine KRX 56 candidates Augment ™ 56 Advaxis Phase 56 Sudhir Agrawal D.Phil 56 Environ Health Perspect 56 refractory cutaneous T 56 CLARITY TIMI 56 MUST CLICK ON 56 Kaydon Corporation Announces 56 TAXUS ATLAS 56 please visit http:/www.vandapharma.com 56 www.pranabio.com 56 TRO# 56 Pruvel ™ 56 PRNewswire FirstCall Vical Incorporated 56 #:#-# [020] 56 WRX STi +# mins 56 Oral Suspension Oral Suspension 56 IRX 2 56 HCV protease 56 recurrent malignant glioma 56 lymphoid malignancies 56 Techni lab 56 PRNewswire FirstCall Ardea Biosciences 56 gastrointestinal stromal 56 Cloretazine R 56 AAEP Convention 56 ASM Biodefense 56 fidaxomicin Phase 3 56 ROADWAYS WILL 56 including cyclosporine methotrexate 56 oncolytic virus therapies 56 NDA Submission 56 Therapeutic Targets 56 initiated Phase 1b 56 Androxal TM 56 Advanced Melanoma 56 EARNINGS YIELD 56 Phase III Clinical Trials 56 NS5B polymerase 56 Randomized Clinical Trial 56 pomalidomide 56 Oligonucleotide Therapeutics Society 56 TRADING HIGHER ON #.#X 56 negative allosteric modulator 56 Inc. NASDAQ ZLCS 56 lexidronam injection PROSTASCINT 56 WILL PARTICIPATE IN 56 acetonide FA 56 bone marrow reticulin deposition 56 phosphate dehydrogenase 56 ® darbepoetin alfa 56 novel topoisomerase 56 GASTRO 56 Serdaxin ® 56 Relapsed Refractory 56 Inc. Nasdaq TPTX 56 following fluoropyrimidine oxaliplatin 56 PRNewswire FirstCall Palatin Technologies 56 www.asco.org 56 Annual Interscience Conference 56 INCHES ACROSS 56 Nasdaq NFLD announced 56 OvaRex ® MAb 56 AND DESTRUCTIVE WINDS IN 56 FBOVESPA 56 AABB Annual Meeting 56 xenograft models 56 signal detection CTSD 56 TLR7 agonist 56 desvenlafaxine succinate 56 pancreatic colon 56 Talabostat 56 Inc. Nasdaq CRTX 56 recurrent glioma 56 IMPDH inhibitor 56 Two Investor Conferences 56 EOquin TM 56 Unternehmen der EquityStory AG 56 ADVISED THAT 56 EGFR HER2 56 TRACON Pharmaceuticals 56 LSE ASM 56 Quinamed 56 Ocular Diseases 56 HCV RESPOND 2 56 Pirfenidone 56 MOST RECENTLY FILED ANNUAL 56 Vidaza R 56 DOES NOT CONSTITUTE AN 56 CR# vcMMAE 56 CCX# B 56 NASDAQ LIPD 56 Enzastaurin 56 ARRY # 56 CORT # 56 Inc. Nasdaq ARQL 56 pivotal bioequivalence 56 visit www.dobimedical.com 56 Novel Approaches 56 NASDAQ BMTI 56 non porcine pancreatic 56 Glucosamine Chondroitin Arthritis 56 lorcaserin Phase 56 antisense inhibitors 56 Epothilone D 56 Cardiol 56 Ribavirin causes 56 Neoplasia 56 WHICH ARE NOT PURELY 56 Hagop M. 56 Interferon Beta 56 GENASIS 56 nucleotide analog 56 hypereosinophilic syndrome 56 Diabetic Macular Edema